JOINN(603127)2024-04-29 10:02Financial Performance - The company's operating revenue for Q1 2024 was RMB 324,809,103.67, representing a decrease of 12.07% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was a loss of RMB 272,222,474.99, a decline of 244.98% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 280,666,741.34, down 251.92% year-on-year[5]. - The weighted average return on net assets was -3.35%, a decrease of 5.62 percentage points compared to the previous year[5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -251.92 million RMB, primarily due to a decrease in net profit from laboratory services and losses from changes in the fair value of biological assets[31]. - Basic and diluted earnings per share were both -244.00 RMB[31]. - Total revenue for Q1 2024 was RMB 324,809,103.67, a decrease of 12.06% compared to RMB 369,386,010.95 in Q1 2023[44]. - Operating profit for Q1 2024 was RMB -293,008,274.73, compared to RMB 214,369,686.98 in Q1 2023, indicating a significant decline[48]. - Net profit for Q1 2024 was RMB -273,363,603.07, a decrease from a net profit of RMB 187,710,078.62 in Q1 2023[48]. - The total comprehensive income for Q1 2024 was -$272.50 million, compared to $183.31 million in Q1 2023, reflecting a substantial decrease in overall performance[50]. - The basic and diluted earnings per share for Q1 2024 were both -$0.36, down from $0.25 in Q1 2023, highlighting a negative shift in profitability[50]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,733,254,487.30, a decrease of 2.93% from the end of the previous year[8]. - The equity attributable to shareholders of the listed company was RMB 7,993,144,600.58, down 3.46% from the end of the previous year[8]. - Non-current assets totaled RMB 2,762,090,308.72, down from RMB 2,905,192,290.36 in the previous period[44]. - Total assets decreased to RMB 9,733,254,487.30 from RMB 10,027,159,630.47[44]. - Total liabilities amounted to RMB 1,739,526,324.07, slightly down from RMB 1,746,119,215.39[44]. - Deferred income tax liabilities were RMB 129,567,321.33, down from RMB 162,342,125.15[44]. Cash Flow - The net cash flow from operating activities was RMB 119,953,519.31, with no applicable year-on-year comparison[5]. - Cash inflows from operating activities in Q1 2024 totaled $492.59 million, a decrease of 22.4% from $635.83 million in Q1 2023[52]. - The net cash flow from operating activities for Q1 2024 was $119.95 million, a significant improvement compared to a net outflow of -$13.67 million in Q1 2023[52]. - Cash outflows for investing activities in Q1 2024 amounted to $179.02 million, compared to $115.88 million in Q1 2023, indicating increased investment expenditures[58]. - The net cash flow from investing activities for Q1 2024 was -$67.56 million, contrasting with a positive cash flow of $106.48 million in Q1 2023[58]. - The cash and cash equivalents at the end of Q1 2024 were $2.87 billion, a slight decrease from $2.96 billion at the end of Q1 2023[58]. - The company reported cash inflows from other operating activities of $18.49 million in Q1 2024, down from $21.31 million in Q1 2023[52]. - The company experienced a foreign exchange loss of $2.80 million on cash and cash equivalents in Q1 2024, compared to a loss of $6.27 million in Q1 2023[58]. Operational Highlights - New orders signed during the reporting period were approximately 400 million RMB, with a year-on-year increase of about 20%, resulting in a total backlog of approximately 3.38 billion RMB[34]. - The laboratory service business contributed a net loss of RMB 21,043,700.00, a decline of 130.01% year-on-year[24]. - Research and development expenses for Q1 2024 were RMB 22,967,298.39, a decrease from RMB 27,611,585.58 in Q1 2023[48]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the report[34]. Shareholder Information - The top ten shareholders held a combined 74.29% of the shares, with the largest shareholder owning 22.29%[32].